<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252495</url>
  </required_header>
  <id_info>
    <org_study_id>ID-080-109</org_study_id>
    <secondary_id>2019-003580-21</secondary_id>
    <nct_id>NCT04252495</nct_id>
  </id_info>
  <brief_title>The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics</brief_title>
  <official_title>An Open-label Phase 1 Study to Investigate the Effect of Moderate Hepatic Impairment Due to Liver Cirrhosis on the Pharmacokinetics of a Single Dose of 25 mg Aprocitentan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the
      effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of
      aprocitentan (ACT-132577).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Healthy subjects will be matched to subjects with moderate hepatic impairment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of aprocitentan</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curves (AUC0-t) of aprocitentan</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve to infinity (AUC0 to inf) of aprocitentan</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events</measure>
    <time_frame>From study treatment administration on Day 1 up to last assessment on End of Study (Day 15)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Subjects with moderate hepatic impairment (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan</intervention_name>
    <description>A single oral dose of 25 mg.</description>
    <arm_group_label>Healthy subjects (Group 2)</arm_group_label>
    <arm_group_label>Subjects with moderate hepatic impairment (Group 1)</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure.

          -  Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at
             screening and a negative urine pregnancy test on Day -1 and must agree to use highly
             effective methods of contraception from screening up to 30 days after study treatment.

          -  A Women of non-childbearing potential (WoNCBP) must meet one of the following
             criteria:

               -  Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy.

               -  Premature ovarian failure confirmed by a specialist gynecologist.

               -  Post-menopausal, defined as 12 consecutive months with amenorrhea prior to
                  screening without alternative medical cause and confirmed with a
                  follicle-stimulating hormone test.

          -  Body mass index of 18.0 to 32.0 kg/m2 (inclusive) at screening.

          -  Normal renal function confirmed by a creatinine clearance at screening according to
             Cockcroft and Gault adjusted to age.

          -  Additional principal inclusion criteria for subjects with moderate hepatic impairment
             (Group 1)

               -  Moderate hepatic function impairment due to liver cirrhosis defined as a score of
                  7-9 (inclusive) according to the Child-Pugh classification.

               -  Systolic blood pressure (SBP) 95 to 160 mmHg, diastolic blood pressure (DBP) 60
                  to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm,
                  after 5 minutes in the supine position at screening and on Day 1 pre-dose.

               -  International normalized ratio equal or less than 2.5 at screening.

               -  Stable concomitant medications for at least 3 weeks prior to screening and up to
                  Day 1 and expected to be stable during the conduct of the study.

          -  Additional principal inclusion criteria for healthy subjects (Group 2)

               -  Healthy on the basis of medical history, physical examination, cardiovascular
                  assessments, and clinical laboratory tests.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Previous exposure to aprocitentan and/or macitentan.

          -  Known hypersensitivity to any excipients of the drug formulation.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

          -  Legal incapacity or limited legal capacity at screening.

          -  Additional exclusion criteria for subjects with moderate hepatic impairment (Group 1)

               -  History or clinical evidence of any disease and/or existence of any surgical or
                  medical condition, which might interfere with the absorption, distribution,
                  metabolism, or excretion (ADME) of the study treatment except for those related
                  to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not
                  allowed).

               -  Hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.

               -  Clinical evidence or suspected acute liver failure as judged by the investigator.

               -  Encephalopathy grade greater than 1.

               -  Severe ascites and/or pleural effusion.

               -  Clinically relevant findings in clinical laboratory tests (hematology,
                  coagulation, clinical chemistry, and urinalysis) at screening &amp; on Day -1, except
                  for those related to liver cirrhosis.

          -  Additional exclusion criteria for healthy subjects (Group 2)

               -  Clinically relevant findings on the physical examination at screening.

               -  History or clinical evidence of any disease and/or existence of any surgical or
                  medical condition, which might interfere with the absorption, distribution,
                  metabolism, or excretion (ADME) of the study treatment (appendectomy and
                  herniotomy allowed, cholecystectomy not allowed).

               -  Clinically relevant findings in clinical laboratory tests (hematology,
                  coagulation,clinical chemistry, and urinalysis) at screening &amp; on Day -1.

               -  Clinically relevant abnormalities on a 12-lead ECG, recorded after 5 min in the
                  supine position at screening &amp; on Day 1 pre-dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Disclosure Desk</last_name>
    <phone>+41 58 844 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biokinetica S.A.</name>
      <address>
        <city>Jozefow</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

